Skip to main content
SpringerLink
Log in

Eli Lilly has announced the withdrawal of Xigris [drotrecogin alfa] in all markets based on trial results

  • News item
  • Published:
Reactions Weekly Aims and scope

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

REFERENCE

  1. Eli Lilly and Company.Lilly Announces Withdrawal of Xigris Following Recent Clinical Trial Results. Media Release: 25 Oct 2011. Available from: URL: http://www.lilly.com

  2. FDA Drug Safety Communication: Voluntary market withdrawal of Xigris [drotrecogin alfa (activated)] due to failure to show a survival benefit. Internet Document: 25 Oct 2011. Available from: URL: http://www.fda.gov/Drugs/DrugSafety/ucm277114.htm

  3. European Medicines Agency.Xigris (drotrecogin alfa (activated)) to be withdrawn due to lack of efficacy. Media Release: 25 Oct 2011. Available from: URL: http://www.ema.europa.eu

Download references

Rights and permissions

Reprints and permissions

About this article

Cite this article

Eli Lilly has announced the withdrawal of Xigris [drotrecogin alfa] in all markets based on trial results. React. Wkly. 1376, 2 (2011). https://doi.org/10.2165/00128415-201113760-00002

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00128415-201113760-00002

Keywords

Search

Navigation